(Reuters) — Healthcare investors can expect a volatile week starting today, when the sector’s biggest financial event hits San Francisco. The annual JP Morgan healthcare conference, in which many healthcare companies present product and financial news to would-be investors, has been credited for helping the January outperformance of the healthcare sector in recent years. But after […]
Trade Show
TCT 2014: Another trial shows no benefit for renal denervation in hypertension
TCT 2014: Boston Scientific’s 1-year data on Lotus TAVI device
TCT 2014 Roundup
Here’s a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:
TCT 2014: Is renal denervation dead or alive?
The efficacy of renal denervation is in doubt and should be confirmed or ruled out in treating resistant hypertension, according to an expert panel in a debate over the once high-flying technology at the Transcatheter Cardiovascular Therapeutics conference in Washington.
TCT 2014: TAVI takes center stage
St. Jude Medical hits ‘pause’ on Portico TAVI device
MedTech Idol VC competition crosses the pond
MedTech Idol is expanding its reach across the pond, opening up a competition for European medical device makers.
The contest, launched stateside last year, is produced by venture capital shop RCT Ventures. The competition exposes start-ups to a group of highly focused medical device investors, allowing the audience to choose the winner.
Heart Rhythm Society 2013 Scientific Session wrap-up
As the Heart Rhythm Society’s 2013 Scientific Sessions are a thing of the past, it is interesting to reflect on what constituted the main thrusts occurring our field. Summarizing thousands of abstracts and hundreds of sessions from scientists (literally) all over the world is impossible, of course. But it did appear a few sea changes in our field are in the works, at least as seen by this humble reporter.
Patient Safety: President Clinton to appear at 1st Patient Safety, Science & Technology Summit
Former President Bill Clinton is slated to headline a roster of healthcare experts at the 1st Patient Safety, Science & Technology Summit next year.
The FDA is there to protect patients? Bullsh*t
Fogarty (l) and Abele
The FDA isn’t capable of living up to its mandate to balance risk and safety for patients, according to medical device legend Dr. Tom Fogarty, a serial medtech entrepreneur who’s also a consultant for the federal watchdog agency.
